Crinetics Pharmaceuticals Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals or view top-rated stocks.

6 equities research analysts have issued 12 month target prices for Crinetics Pharmaceuticals' stock. Their CRNX stock forecasts range from $35.00 to $45.00. On average, they expect Crinetics Pharmaceuticals' stock price to reach $41.00 in the next year. This suggests a possible upside of 117.5% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Crinetics Pharmaceuticals' stock was trading at $28.41 at the beginning of 2022. Since then, CRNX stock has decreased by 33.7% and is now trading at $18.85.
View the best growth stocks for 2022 here.

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) released its quarterly earnings data on Thursday, May, 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.17. The firm earned $3.13 million during the quarter.
View Crinetics Pharmaceuticals' earnings history.

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Crinetics Pharmaceuticals include Mirati Therapeutics (MRTX), Cerevel Therapeutics (CERE), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Cytokinetics (CYTK), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), Roivant Sciences (ROIV), AbCellera Biologics (ABCL), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT) and Blueprint Medicines (BPMC).
View all of CRNX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRNX stock can currently be purchased for approximately $18.85.

Crinetics Pharmaceuticals (NASDAQ:CRNX) has a market capitalization of $1.01 billion and generates $1.08 million in revenue each year. The company earns $-107,640,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis.

Crinetics Pharmaceuticals employs 143 workers across the globe.

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The official website for Crinetics Pharmaceuticals is www.crinetics.com. The company can be reached via phone at (858) 450-6464 or via email at ir@crinetics.com.